Nano-X Imaging (NNOX) Q3 2025 earnings summary

Executive summary

• Transitioned from hardware-focused to a comprehensive imaging platform with a three-pillar strategy: technology expansion, AI integration, and operational efficiency.

• Revenue for Q3 2025 was $3.4 million, up from $3.0 million in Q3 2024, driven by teleradiology and AI solutions.

• Net loss for Q3 2025 was $13.7 million, slightly higher than $13.6 million in Q3 2024.

• Completed acquisition of VasoHealthcare IT to expand AI solutions and accelerate recurring revenue streams.

• Expanded global presence with new distribution agreements and clinical collaborations, including Cedars-Sinai and Olympe Imagerie.

Financial highlights

• Q3 2025 GAAP net loss was $13.7 million, slightly higher than $13.6 million in Q3 2024.

• Revenue for Q3 2025 was $3.4 million, up from $3.0 million year-over-year.

• Non-GAAP net loss attributable to ordinary shares was $9.9 million, up from $8.7 million in Q3 2024.

• Cash, cash equivalents, and marketable securities totaled $55.5 million as of September 30, 2025.

• Teleradiology services revenue grew to $3.1 million in Q3 2025, with GAAP gross profit margin improving to 25% from 13% year-over-year.

Outlook and guidance

• 2026 revenue guidance set at $35 million, superseding all prior outlooks, with growth expected to ramp up throughout the year.

• AI business segment projected to reach EBITDA break-even on a quarterly basis in 2026; company-wide EBITDA break-even targeted for 2027.

• Expects to have over 100 clinical, demo, and commercial units deployed worldwide by year-end 2025.

• VasoHealthcare IT expected to contribute approximately $4 million in annual revenue.